Chapel Hill, North Carolina 27599

  • Prostate Cancer


RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have relapsed prostate cancer following radiation therapy or radical prostatectomy.

Study summary:

OBJECTIVES: - Determine the effect of celecoxib on prostate-specific antigen (PSA) levels in patients with prostate cancer in biochemical relapse after prior definitive radiotherapy or radical prostatectomy. - Compare the PSA doubling times in patients treated with this drug vs historical controls. - Compare the PSA doubling times in patients treated with this drug vs pretreatment PSA values. - Determine the time to clinical recurrence in patients treated with this drug. OUTLINE: Patients receive oral celecoxib twice daily. Treatment continues for 5 years in the absence of disease progression. Patients may continue treatment beyond 5 years at the discretion of the treating physician. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of clinically localized adenocarcinoma of the prostate - T1 or T2 disease - Received prior primary treatment with definitive radiotherapy (at least 5,500 cGy) OR radical prostatectomy - Biochemical relapse within 5 years after prior primary therapy, defined as 1 of the following: - Detectable and rising prostate-specific antigen (PSA) after surgery (at least 2 values above the residual cancer detection limit of the assay) - PSA at least 2 values above 1 ng/mL OR at least 3 rising values at any level after radiotherapy - PSA no greater than 10 ng/mL PATIENT CHARACTERISTICS: Age - Not specified Performance status - ECOG 0-2 Life expectancy - Not specified Hematopoietic - Not specified Hepatic - ALT no greater than 2.5 times upper limit of normal Renal - Creatinine normal Other - No allergy to cyclooxygenase-2 inhibitors, aspirin, nonsteroidal anti-inflammatory drugs, or sulfa drugs - No untreated peptic ulcer disease PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - More than 6 months since prior adjuvant or neoadjuvant hormonal therapy - Duration of prior adjuvant or neoadjuvant hormonal therapy must have been no more than 6 months Radiotherapy - See Disease Characteristics - Prior salvage radiotherapy after prostatectomy allowed Surgery - See Disease Characteristics



Primary Contact:

Study Chair
Raj S. Pruthi, MD
UNC Lineberger Comprehensive Cancer Center

Backup Contact:


Location Contact:

Chapel Hill, North Carolina 27599
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.